Celgene Strengthens Immuno-oncology Franchise with Beigene’s BGB-A317
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 7 (Table of Contents)
Published: 17 Jul-2017
DOI: 10.3833/pdr.v2017.i7.2262 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In addition to durvalumab, Celgene has gained another immuno-oncology candidate - BGB-A317 – a PD-1 inhibitor from Beigene...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS